Leiden Startup Advances Early Cancer Detection Technology
Leiden, Friday, 13 December 2024.
Idris Oncology develops an innovative device to capture cancer DNA from blood, which could revolutionize early cancer detection and treatment, showcasing the Netherlands’ biotech leadership.
Revolutionary DNA Capture Technology
Idris Oncology, founded by Hans Peter Mulder and Peter Wiegman, has developed an innovative medical device that functions like a ‘fishing wire’ to capture cancer DNA in the bloodstream [1]. This healthtech startup, based in the prestigious Leiden Bio Science Park, is addressing one of the most significant challenges in cancer diagnostics - the detection of early-stage tumors or monitoring nearly eliminated tumors after treatment [1].
How the Technology Works
The technology represents a paradigm shift in cancer detection methodology. As explained by co-founder Hans Peter Mulder, ‘Rather than taking a bucket of water out of the river, we use a fishing wire’ [1]. This innovative approach allows for more precise capture of cancer DNA in the bloodstream, potentially enabling earlier detection of tumors when they are small or monitoring their disappearance during treatment [1]. The device is currently in early stages of product development, with human testing documentation being prepared [1].
Future Impact and Development
The startup’s vision extends beyond current applications, with aspirations to develop implants that could monitor key biomarkers for early disease detection [1]. The company envisions a future where their technology could be used preventively, particularly for individuals around age 50, to detect early signs of cancer [1]. However, as noted by Hans Peter Mulder, ‘Developing any invasive medical device is a lengthy process, especially as we fall under the highest regulatory class,’ suggesting a development timeline of approximately ten years [1].
Strategic Location and Support
The company’s location in Leiden Bio Science Park provides crucial advantages, offering legitimacy and community support that enhances credibility with venture capitalists and medical professionals [1]. This strategic positioning within one of the Netherlands’ premier biotech hubs strengthens the company’s ability to develop and eventually commercialize their groundbreaking technology [1].